How should methadone and buprenorphine treatment be organized and regulated? A comparison between two systems in the context of a EUROPAD conference in Brussels

Heroin Addiction and Related Clinical Problems

Volumn 14, Issue 1, 2012, Pages 5-9

  Ulmer, Albrecht ^a   Lamy, Dominique ^b   Reisinger, Marc ^c   Haraldsen, Martin ^a   Maremmani, Icro ^d,e   Newman, Robert ^f  

^a Alto SSMG ^*

^b Alto SSMG   (Belgium)

^c EUROPAD   (Belgium)

^d World Federation for the Treatment of Opioid Dependence WFTOD   (Italy)

^e World Federation for the Treatment of Opioid Dependence WFTOD   (United States)

^f BETH ISRAEL MEDICAL CENTER   (United States)

Author keywords

Buprenorphine treatment; Methadone treatment; Regulations; Therapeutic system

Indexed keywords

BUPRENORPHINE; METHADONE; OPIATE AGONIST;

ARTICLE; BELGIUM; BUPRENORPHINE TREATMENT; COMPARATIVE STUDY; CONTROLLED STUDY; COUNSELING; DRUG DEPENDENCE TREATMENT; DRUG DOSE; EDUCATION; EVALUATION; GERMANY; LEGAL ASPECT; LICENCE; MEDICAL PRACTICE; METHADONE TREATMENT; OPIATE ADDICTION; OPIATE AGONIST TREATMENT; OUTCOME ASSESSMENT; PHARMACIST; PHYSICIAN; PRESCRIPTION; PRIORITY JOURNAL; PSYCHOSOCIAL CARE; QUALITY CONTROL; SOCIAL NETWORK; SOCIAL SUPPORT; SOCIETY; URINALYSIS;

EID: 84858423409     PISSN: 15921638     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (0)